An interventional study of ECG Analysis Software AiTiALVDD and ECG Analysis Software AiTiALVSD in AF - Atrial Fibrillation, sponsored by Korea University Anam Hospital. Not yet recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Korea University Anam Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 208 studies in Atrial Fibrillation with a site in Korea, Republic of — 60 open to participants now, 68 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.
Among the 208 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 32nd largest by planned enrollment of the 143 interventional ones that give a count, is one of 17 that started in 2026, is one of 90 with no phase, reaches primary completion later than 55 of the 67 other live ones, and was the 207th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →60 of the 208 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
Oslo University Hospital · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 18+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
208 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 22 · Phase 4 22
First in 2005; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,006 is above the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Median enrollment 300 across the 143 interventional studies, 1,181 across the 65 observational. Of the 100 that completed or were terminated, 33 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 208 have an industry lead sponsor. The 10 most frequent:
Korea University Anam Hospital is the lead sponsor of 113 studies on the registry; 32 are open to participants now.
Korea University Anam Hospital has 8 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
10 of the studies in Atrial Fibrillation with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07641582Seoul St. Mary's HospitalPrediction of Atrial Fibrillation Using Polygenic Risk Score | 2026-12-30 |
| NCT05507749Seoul National University HospitalCyroablation for Pulmonary Vein Isolation Alone in Patients With Early Persistent AF Assessed by Continuous Monitoring | 2026-12-31 |
| NCT05794386Seoul National University HospitalSCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation | 2026-12-31 |
| NCT07607093Samsung Medical CenterEfficacy of Early Rhythm Control in AF With TR Patients | 2027-02-28 |
Add all 10 to your calendar (.ics) → With an account.
Among the 208 studies in Atrial Fibrillation with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial fibrillation (AF) is the most common type of irregular heartbeat in adults. People with AF may also have other heart problems, including reduced heart pumping function or diseases affecting the heart muscle or heart valves. Identifying these problems early is important because the condition of the heart can affect treatment decisions and long-term care.
An ultrasound examination of the heart, called transthoracic echocardiography (TTE) or an echocardiogram, is commonly used to check how well the heart pumps blood and to look for structural problems, such as heart valve disease. However, an echocardiogram requires special equipment and trained healthcare professionals to perform and interpret the examination. Because of these requirements, it may not always be available when needed. This can be particularly challenging in situations where heart function needs to be evaluated quickly, such as when a patient with AF has a very fast heart rate. Delays may also occur in outpatient settings because of limited availability of echocardiography.
Artificial intelligence (AI) technology may provide an additional way to identify patients who are more likely to have heart problems and who may benefit from further evaluation. A standard 12-lead electrocardiogram (ECG) is a simple and widely available test that records the electrical activity of the heart. AI-based computer programs can analyze information contained in an ECG that may not be easily recognized through routine interpretation.
This study will use two AI-based ECG programs, called AiTiALVSD and AiTiALVDD. AiTiALVSD analyzes a standard 12-lead ECG to identify patients who may have reduced heart pumping function. Previous studies have evaluated this program in different clinical settings, including patients with AF and a fast heart rate.
AiTiALVDD analyzes the ECG for signs that may be associated with difficulty in the heart relaxing and filling with blood. Problems with heart relaxation and filling may occur in several types of heart disease, including heart valve disease, abnormal thickening of the heart muscle, heart disease related to high blood pressure, diseases affecting the heart muscle, and coronary artery disease. Importantly, some patients may have these conditions even when the heart's overall pumping function is normal. Therefore, evaluating only pumping function may not identify all patients who have important underlying heart disease.
By using AiTiALVSD and AiTiALVDD together, this study aims to evaluate a broader AI-based approach to identifying heart problems in patients with AF. AiTiALVSD may help identify patients who are more likely to have reduced heart pumping function, while AiTiALVDD may provide additional information about possible problems with heart relaxation and filling. A high-risk result from AiTiALVDD may serve as a signal that further heart evaluation should be considered, including evaluation for significant heart valve disease or other underlying structural heart conditions.
The purpose of this study is to evaluate whether using these two AI-based ECG programs together can help identify patients with AF who may have previously unrecognized problems with heart function or underlying heart disease. Patients identified by the AI analysis as being at higher risk may receive further evaluation as appropriate to determine whether additional heart disease is present.
The study will also evaluate the clinical usefulness of this AI-based ECG approach in routine care. The goal is not to replace an echocardiogram or a physician's clinical assessment. Instead, AI-based ECG analysis may serve as an additional screening tool to help healthcare professionals identify patients who may benefit from further cardiac testing.
By using information from a routinely performed ECG, this approach may help support earlier and more efficient evaluation of heart function and underlying heart disease in patients with AF. The results of this study will help determine whether combining AiTiALVSD and AiTiALVDD can provide useful information for deciding which patients may need additional cardiac evaluation and whether this approach can improve the process of identifying clinically important heart conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pharmacologic treatment will be initiated after TTE is performed, in accordance with guideline recommendations. * Rate control: In accordance with guideline recommendations, the choice of rate-control agent may be based on LV EF (≤40% or not). However, in patients requiring acute rate control, agents that can be used regardless of LV EF (beta-blocker, digoxin) may be used without prior TTE.1 * Rhythm control: In accordance with guideline recommendations, antiarrhythmic drug therapy may be initiated after assessment of LV EF and structural heart disease. Because oral amiodarone is not recommended as first-line therapy when LV EF \>40%, it may not be used preferentially without information on LV EF. 1,2 * When underlying heart failure is suspected, guideline-recommended pharmacotherapy will also be administered; however, when acute or congestive heart failure is suspected, agents that can be used without LV EF information (e.g., diuretics) may be initiated.
Device: ECG Analysis Software AiTiALVSD
Guideline-directed AF pharmacotherapy may be initiated based on the AI-predicted LV EF obtained on the day of enrollment. Because patients with AF undergo a 12-lead ECG for clinical purposes, in the investigational group the AI-predicted LV EF becomes available immediately once the AI-enabled 12-lead ECG is performed. * TTE may also be performed in the investigational group, in accordance with guideline recommendations, to assess structural heart disease and left atrial substrate, and treatment may be modified based on the TTE results. * Rate control: The choice of agent may be based on the AI-predicted LV EF.1 * Rhythm control: If the AI-predicted LV EF is \>40%, there is no history of coronary artery disease, and there is no suspicion of moderate-to-severe valvular disease (e.g., no murmur), a Class IC antiarrhythmic drug (propafenone, flecainide, etc.) may be used in accordance with guideline recommendations. If the AI-predicted LV EF is ≤40%, oral amiodarone may be administered.1,2
Device: ECG Analysis Software AiTiALVDD
* Classification code (grade): B2ABXA1(3) * Mechanism of action: When biosignal data (raw 12-lead ECG data) measured by an ECG device are automatically transmitted or uploaded, an artificial intelligence algorithm displays a score and risk level for the likelihood of left ventricular diastolic dysfunction, for use as a diagnostic aid. Analyzed ECGs can be stored in HL7 aECG XML, JPG, or DICOM format.
* Classification code (grade): E01020.01(2) * Mechanism of action: When biosignal data (12-lead ECG) from an ECG device are automatically transmitted, or uploaded by the user, this software applies an artificial intelligence algorithm to the ECG data to predict the likelihood of left ventricular systolic dysfunction and displays the analysis results on a web-based screen.
Major adverse cardiovascular events (MACE), a composite outcome
Major adverse cardiovascular events (MACE) will be assessed as a composite outcome comprising all-cause death, cardiovascular death, stroke (ischemic or hemorrhagic), acute coronary syndrome, and cardiovascular hospitalization. The outcome will be reported as the number of participants experiencing at least one of these events during the follow-up period. Participants experiencing multiple component events will be counted only once in the composite outcome.
Time frame: 1year
Number of Participants with All-Cause Death
The number of participants who die from any cause during the follow-up period will be assessed. Each participant will be counted only once. Unit of Measure - Number of participants
Time frame: 1year
Number of Participants with Stroke (Ischemic or Hemorrhagic)
The number of participants experiencing at least one ischemic or hemorrhagic stroke during the follow-up period will be assessed. Each participant will be counted only once, regardless of the number of stroke events. Unit of measure - number of participants
Time frame: 1year
Number of Participants with Acute Myocardial Infarction
The number of participants experiencing at least one acute myocardial infarction during the follow-up period will be assessed. Each participant will be counted only once, regardless of the number of events. Unit of Measure- Number of participants
Time frame: 1year
Number of Participants Hospitalized for Heart Failure
The number of participants experiencing at least one hospitalization for heart failure during the follow-up period will be assessed. Each participant will be counted only once, regardless of the number of hospitalizations. Unit of Measure- Number of participants
Time frame: 1year
Number of Participants with an Emergency Room Visit or Hospitalization for Cardiovascular Causes
The number of participants experiencing at least one emergency room (ER) visit or hospitalization for cardiovascular causes during the follow-up period will be assessed. Participants experiencing both an ER visit and hospitalization for cardiovascular causes will be counted only once. Unit of Measure- Number of participants
Time frame: 1year
Percentage of Participants Achieving Atrial Fibrillation Rate Control
Atrial fibrillation (AF) rate control will be assessed as the percentage of participants achieving a heart rate of less than 110 beats per minute (bpm) during the specified assessment period. Unit of Measure: Percentage of participants
Time frame: 1year
Time to Achievement of Atrial Fibrillation Rate Control
Time to AF rate control will be measured in days from the protocol-defined starting point to the first documented achievement of a heart rate of less than 110 bpm. Unit of Measure: Days
Time frame: 1year
Time to Initiation of Oral Antiarrhythmic Drug Therapy
Time to initiation of oral antiarrhythmic drug therapy will be measured in days from the protocol-defined starting point to the first documented initiation of oral antiarrhythmic drug therapy. Unit of Measure: Days
Time frame: 1year
Time to Atrial Fibrillation Catheter Ablation
Time to atrial fibrillation (AF) catheter ablation will be measured in days from the protocol-defined starting point to the date of the first AF catheter ablation procedure. Unit of Measure: Days
Time frame: 1year
Time to Restoration of Sinus Rhythm
Time to restoration of sinus rhythm will be measured in days from the protocol-defined starting point to the first documented restoration of sinus rhythm. Unit of Measure: Days
Time frame: 1year
AUC for LV Systolic Dysfunction
The predictive performance of the artificial intelligence (AI) model for identifying left ventricular (LV) systolic dysfunction will be assessed using the area under the receiver operating characteristic curve (AUC). AUC values range from 0 to 1, with higher values indicating better discrimination. The AUC of the AI model will be compared with that of N-terminal pro-B-type natriuretic peptide (NT-proBNP).
Time frame: 1year
Sensitivity for LV Systolic Dysfunction
Sensitivity of the AI model for identifying LV systolic dysfunction will be calculated as the percentage of participants with reference-standard-confirmed LV systolic dysfunction who are correctly identified by the AI model. Values range from 0% to 100%, with higher values indicating better sensitivity.
Time frame: 1year
Specificity for LV Systolic Dysfunction
Specificity of the AI model for identifying LV systolic dysfunction will be calculated as the percentage of participants without reference-standard-confirmed LV systolic dysfunction who are correctly identified as negative by the AI model. Values range from 0% to 100%, with higher values indicating better specificity.
Time frame: 1year
Positive Predictive Value
Positive predictive value (PPV) will be calculated as the percentage of participants with a positive AI prediction for LV systolic dysfunction who have reference-standard-confirmed LV systolic dysfunction. Values range from 0% to 100%, with higher values indicating greater positive predictive value.
Time frame: 1year
Negative Predictive Value
Negative predictive value (NPV) will be calculated as the percentage of participants with a negative AI prediction for LV systolic dysfunction who do not have reference-standard-confirmed LV systolic dysfunction. Values range from 0% to 100%, with higher values indicating greater negative predictive value.
Time frame: 1year
Atrial Fibrillation Burden at 1 Year Assessed by 3-Day Holter Electrocardiography
Atrial fibrillation (AF) burden at 1 year will be assessed using 3-day Holter electrocardiography (ECG) monitoring. AF burden will be calculated as the total duration of AF episodes divided by the total analyzable ECG monitoring time, multiplied by 100. AF burden will be expressed as a percentage, ranging from 0% to 100%, with higher percentages indicating greater AF burden.
Time frame: 1year
Change From Baseline to 1 Year in Atrial Fibrillation-Related Quality of Life Assessed by the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT)
Atrial fibrillation (AF)-related quality of life will be assessed using the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT) at baseline and 1 year. The AFEQT overall score ranges from 0 to 100, with higher scores indicating better AF-related quality of life. Change from baseline will be calculated as the score at 1 year minus the baseline score. A positive change indicates an improvement in AF-related quality of life.
Time frame: Baseline and 1 year
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.
Of 795 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 36 months is close to that.
Counting every sponsor, half of 1,050 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korea University Anam Hospital →